Enforcement Report - Week of September 27, 2023
BD (Becton, Dickinson and Company), a leading global medical technology company, and CerTest Biotec, announced the CE mark for a molecular test that can detect and distinguish between the Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) SARS-CoV-2 variants.
Becton Dickinson on Thursday reported third fiscal quarter revenues of $4.9 billion, growing 26.9% year over year on a reported basis driven by its base business, beating Street expectations of $4.5 billion.
Lonza has confirmed it is interested in buying Capsugel.
BD RX`s Generic Dexamethasone Sodium Phosphate approved in US…
A warning has been issued by the U.S. FDA for health professionals not to administer medicinal drug products prepared in Becton-Dickinson syringes. This is due to a drug potency issue.